Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels

Javier Pacheco-Quinto, Elena B. Rodriguez de Turco, Steven DeRosa, Altovise Howard, Felix Cruz-Sanchez, Kumar Sambamurti, Lorenzo Refolo, Suzana Petanceska, Miguel Pappolla

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Recent epidemiological and clinical data suggest that elevated serum homocysteine levels may increase the risk of developing Alzheimer's disease (AD), but the underlying mechanisms are unknown. We tested the hypothesis that high serum homocysteine concentration may increase amyloid beta-peptide (Aβ) levels in the brain and could therefore accelerate AD neuropathology. For this purpose, we mated a hyperhomocysteinemic CBStm1Unc mouse carrying a heterozygous dominant mutation in cystathionine-beta-synthase (CBS*) with the APP*/PS1* mouse model of brain amyloidosis. The APP*/PS1*/CBS* mice showed significant elevations of serum homocysteine levels compared to the double transgenic APP*/PS1* model of amyloidosis. Results showed that female (but not male) APP*/PS1*/CBS* mice exhibited significant elevations of Aβ40 and Aβ42 levels in the brain. Correlations between homocysteine levels in serum and brain Aβ levels were statistically significant. No increases in beta secretase activity or evidence of neuronal cell loss in the hyperhomocysteinemic mice were found. The causes of neuronal dysfunction and degeneration in AD are not fully understood, but increased production of Aβ seems to be of major importance. By unveiling a link between homocysteine and Aβ levels, these findings advance our understanding on the mechanisms involved in hyperhomocysteinemia as a risk factor for AD.

Original languageEnglish (US)
Pages (from-to)651-656
Number of pages6
JournalNeurobiology of Disease
Volume22
Issue number3
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Homocysteine
Amyloidosis
Amyloid
Cystathionine beta-Synthase
Alzheimer Disease
Peptides
Brain
Serum
Amyloid Precursor Protein Secretases
Hyperhomocysteinemia
Amyloid beta-Peptides
Mutation

Keywords

  • Aβ40
  • Aβ42
  • Alzheimer's disease
  • Amyloidosis
  • Brain
  • Hyperhomocysteinemia

ASJC Scopus subject areas

  • Neurology

Cite this

Pacheco-Quinto, J., Rodriguez de Turco, E. B., DeRosa, S., Howard, A., Cruz-Sanchez, F., Sambamurti, K., ... Pappolla, M. (2006). Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels. Neurobiology of Disease, 22(3), 651-656. https://doi.org/10.1016/j.nbd.2006.01.005

Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels. / Pacheco-Quinto, Javier; Rodriguez de Turco, Elena B.; DeRosa, Steven; Howard, Altovise; Cruz-Sanchez, Felix; Sambamurti, Kumar; Refolo, Lorenzo; Petanceska, Suzana; Pappolla, Miguel.

In: Neurobiology of Disease, Vol. 22, No. 3, 06.2006, p. 651-656.

Research output: Contribution to journalArticle

Pacheco-Quinto, J, Rodriguez de Turco, EB, DeRosa, S, Howard, A, Cruz-Sanchez, F, Sambamurti, K, Refolo, L, Petanceska, S & Pappolla, M 2006, 'Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels', Neurobiology of Disease, vol. 22, no. 3, pp. 651-656. https://doi.org/10.1016/j.nbd.2006.01.005
Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, Howard A, Cruz-Sanchez F, Sambamurti K et al. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels. Neurobiology of Disease. 2006 Jun;22(3):651-656. https://doi.org/10.1016/j.nbd.2006.01.005
Pacheco-Quinto, Javier ; Rodriguez de Turco, Elena B. ; DeRosa, Steven ; Howard, Altovise ; Cruz-Sanchez, Felix ; Sambamurti, Kumar ; Refolo, Lorenzo ; Petanceska, Suzana ; Pappolla, Miguel. / Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels. In: Neurobiology of Disease. 2006 ; Vol. 22, No. 3. pp. 651-656.
@article{fab2b3f4c52b4b619b1bfa645ae6a088,
title = "Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels",
abstract = "Recent epidemiological and clinical data suggest that elevated serum homocysteine levels may increase the risk of developing Alzheimer's disease (AD), but the underlying mechanisms are unknown. We tested the hypothesis that high serum homocysteine concentration may increase amyloid beta-peptide (Aβ) levels in the brain and could therefore accelerate AD neuropathology. For this purpose, we mated a hyperhomocysteinemic CBStm1Unc mouse carrying a heterozygous dominant mutation in cystathionine-beta-synthase (CBS*) with the APP*/PS1* mouse model of brain amyloidosis. The APP*/PS1*/CBS* mice showed significant elevations of serum homocysteine levels compared to the double transgenic APP*/PS1* model of amyloidosis. Results showed that female (but not male) APP*/PS1*/CBS* mice exhibited significant elevations of Aβ40 and Aβ42 levels in the brain. Correlations between homocysteine levels in serum and brain Aβ levels were statistically significant. No increases in beta secretase activity or evidence of neuronal cell loss in the hyperhomocysteinemic mice were found. The causes of neuronal dysfunction and degeneration in AD are not fully understood, but increased production of Aβ seems to be of major importance. By unveiling a link between homocysteine and Aβ levels, these findings advance our understanding on the mechanisms involved in hyperhomocysteinemia as a risk factor for AD.",
keywords = "Aβ40, Aβ42, Alzheimer's disease, Amyloidosis, Brain, Hyperhomocysteinemia",
author = "Javier Pacheco-Quinto and {Rodriguez de Turco}, {Elena B.} and Steven DeRosa and Altovise Howard and Felix Cruz-Sanchez and Kumar Sambamurti and Lorenzo Refolo and Suzana Petanceska and Miguel Pappolla",
year = "2006",
month = "6",
doi = "10.1016/j.nbd.2006.01.005",
language = "English (US)",
volume = "22",
pages = "651--656",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels

AU - Pacheco-Quinto, Javier

AU - Rodriguez de Turco, Elena B.

AU - DeRosa, Steven

AU - Howard, Altovise

AU - Cruz-Sanchez, Felix

AU - Sambamurti, Kumar

AU - Refolo, Lorenzo

AU - Petanceska, Suzana

AU - Pappolla, Miguel

PY - 2006/6

Y1 - 2006/6

N2 - Recent epidemiological and clinical data suggest that elevated serum homocysteine levels may increase the risk of developing Alzheimer's disease (AD), but the underlying mechanisms are unknown. We tested the hypothesis that high serum homocysteine concentration may increase amyloid beta-peptide (Aβ) levels in the brain and could therefore accelerate AD neuropathology. For this purpose, we mated a hyperhomocysteinemic CBStm1Unc mouse carrying a heterozygous dominant mutation in cystathionine-beta-synthase (CBS*) with the APP*/PS1* mouse model of brain amyloidosis. The APP*/PS1*/CBS* mice showed significant elevations of serum homocysteine levels compared to the double transgenic APP*/PS1* model of amyloidosis. Results showed that female (but not male) APP*/PS1*/CBS* mice exhibited significant elevations of Aβ40 and Aβ42 levels in the brain. Correlations between homocysteine levels in serum and brain Aβ levels were statistically significant. No increases in beta secretase activity or evidence of neuronal cell loss in the hyperhomocysteinemic mice were found. The causes of neuronal dysfunction and degeneration in AD are not fully understood, but increased production of Aβ seems to be of major importance. By unveiling a link between homocysteine and Aβ levels, these findings advance our understanding on the mechanisms involved in hyperhomocysteinemia as a risk factor for AD.

AB - Recent epidemiological and clinical data suggest that elevated serum homocysteine levels may increase the risk of developing Alzheimer's disease (AD), but the underlying mechanisms are unknown. We tested the hypothesis that high serum homocysteine concentration may increase amyloid beta-peptide (Aβ) levels in the brain and could therefore accelerate AD neuropathology. For this purpose, we mated a hyperhomocysteinemic CBStm1Unc mouse carrying a heterozygous dominant mutation in cystathionine-beta-synthase (CBS*) with the APP*/PS1* mouse model of brain amyloidosis. The APP*/PS1*/CBS* mice showed significant elevations of serum homocysteine levels compared to the double transgenic APP*/PS1* model of amyloidosis. Results showed that female (but not male) APP*/PS1*/CBS* mice exhibited significant elevations of Aβ40 and Aβ42 levels in the brain. Correlations between homocysteine levels in serum and brain Aβ levels were statistically significant. No increases in beta secretase activity or evidence of neuronal cell loss in the hyperhomocysteinemic mice were found. The causes of neuronal dysfunction and degeneration in AD are not fully understood, but increased production of Aβ seems to be of major importance. By unveiling a link between homocysteine and Aβ levels, these findings advance our understanding on the mechanisms involved in hyperhomocysteinemia as a risk factor for AD.

KW - Aβ40

KW - Aβ42

KW - Alzheimer's disease

KW - Amyloidosis

KW - Brain

KW - Hyperhomocysteinemia

UR - http://www.scopus.com/inward/record.url?scp=33744788667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744788667&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2006.01.005

DO - 10.1016/j.nbd.2006.01.005

M3 - Article

VL - 22

SP - 651

EP - 656

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - 3

ER -